Emergent Biosolutions, Inc. (EBS) financial statements (2022 and earlier)

Company profile

Business Address 400 PROFESSIONAL DR, SUITE 400
GAITHERSBURG, MD 20879
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments576621168112178272313
Cash and cash equivalents576621168112178272313
Restricted cash and investments00001  
Receivables275231275271146148127
Inventory, net of allowances, customer advances and progress billings3513072232061437477
Inventory3513072232061437477
Contract with customer, asset22   
Deferred costs   1   
Other undisclosed current assets49372030171622
Total current assets:1,2721,196686621485510539
Noncurrent Assets
Property, plant and equipment800644542510407376332
Intangible assets, net (including goodwill)8309309801,02116975112
Goodwill225267267260494155
Intangible assets, net (excluding goodwill)6056637137621203457
Other noncurrent assets571137714627
Other undisclosed noncurrent assets  42633654
Total noncurrent assets:1,6871,6871,6411,609585460505
TOTAL ASSETS:2,9592,8832,3272,2291,0709701,044
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities269268197174847687
Accounts payable1291369581423546
Accrued liabilities52474031566
Employee-related liabilities89856258383535
Taxes payable   5   
Debt  1310 20 
Deferred revenue and credits1378
Contract with customer, liability11
Other liabilities73834    
Other undisclosed current liabilities323436235
Total current liabilities:374385216200100106100
Noncurrent Liabilities
Long-term debt and lease obligation80984179878513248253
Long-term debt, excluding current maturities80984179878513248253
Liabilities, other than long-term debt15721113417934108
Deferred revenue and credits1787
Accounts payable and accrued liabilities   1113  
Deferred revenue556 
Contract with customer, liability8663
Deferred tax liabilities, net68   
Deferred income tax liabilities9553 
Other liabilities53684938521
Business combination, contingent consideration, liability534     
Other undisclosed noncurrent liabilities  9054101023
Total noncurrent liabilities:9661,0521,0231,01858268284
Total liabilities:1,3401,4361,2391,219158374384
Stockholders' equity
Stockholders' equity attributable to parent1,6191,4471,0891,011912596660
Common stock0000000
Treasury stock, value(152)(40)(40)(40)(39)(6)(6)
Additional paid in capital829785716689618352318
Accumulated other comprehensive loss(16)(25)(10)(6)(4)(4)(3)
Retained earnings958727422367337254351
Total stockholders' equity:1,6191,4471,0891,011912596660
TOTAL LIABILITIES AND EQUITY:2,9592,8832,3272,2291,0709701,044

Income statement (P&L) ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Revenues1,7931,5551,106782561489523
Revenue, net561489523
Cost of revenue
(Cost of Goods and Services Sold)
 (524)(434)(322)(196)(131)(124)
Gross profit:1,7931,031673460365357398
Operating expenses(1,440)(1,122)(992) (241)(252)(302)
Other undisclosed operating income (loss) 524434(370)   
Operating income:3534341149012410696
Nonoperating expense(38)(27)(37)(8)(6)(6)(6)
Investment income, nonoperating    211
Other nonoperating income (expense)(4)522(1)0(0)
Interest and debt expense(35)(31)(38)(10)(7)(8)(7)
Other undisclosed income from continuing operations before equity method investments, income taxes 313810787
Income from continuing operations before equity method investments, income taxes:28040777821199990
Other undisclosed income from continuing operations before income taxes35      
Income from continuing operations before income taxes:31440777821199990
Income tax expense(84)(102)(23)(19)(36)(37)(27)
Income from continuing operations:2313055563836363
Loss from discontinued operations     (11) 
Net income available to common stockholders, basic:2313055563835263
Interest on convertible debt     33
Net income available to common stockholders, diluted:2313055563835566

Comprehensive Income ($ in millions)

12/31/2021
12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
Net income:2313055563835263
Other comprehensive loss  (0)(2)   
Other undisclosed comprehensive income (loss)    1(2)0
Comprehensive income:2313055461835063
Other undisclosed comprehensive income (loss), net of tax, attributable to parent9(15)(4)    
Comprehensive income, net of tax, attributable to parent:2402905061835063

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: